Radionuclide therapy using 131I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression

Li, Wei; Liu, Zhongyun; Li, Chengxia; Li, Ning; Fang, Lei; Chang, Jin; Tan, Jian

doi:10.1007/s00432-015-2067-2

Cited by 28 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At present, clinical monoclonal antibody (mAb)‐mediated radionuclide therapy (radioimmunotherapy, RIT) has become an attractive therapeutic application, as it has the ability to target both the primary tumor site as well as disseminated diseased tissue . Owing to the suitable emission characteristics, facile and affordable production, and amenable chemical properties, 131 I was widespread used as an ideal radionuclide for RIT . Obviously, the method of RIT is based on the selective accumulation of radionuclide‐containing pharmaceuticals only in tumor tissues to acquire high efficiency with minimal health risks .…”

Section: Introductionmentioning

confidence: 99%

“…7 Owing to the suitable emission characteristics, facile and affordable production, and amenable chemical properties, 131 I was widespread used as an ideal radionuclide for RIT. 8 Obviously, the method of RIT is based on the selective accumulation of radionuclide-containing pharmaceuticals only in tumor tissues to acquire high efficiency with minimal health risks. 9,10 α-Fetoprotein (AFP), a type of specific liver cancer marker, is overexpressed in over 70% of primary hepatic carcinomas.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

¹³¹I radiolabeled immune albumin nanospheres loaded with doxorubicin for in vivo combinatorial therapy

Zhang

et al. 2018

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

For the purpose of providing new insights for high-efficiency radiochemotherapy of hepatoma, a radioimmunotherapy and chemotherapy combinatorial therapy albumin nanospheres I-antiAFPMcAb-DOX-BSA-NPs was designed and prepared. It was obtained in a high radiolabeling yield approximately 65% with the radiochemical purity of over 98%. The transmission electron microscope showed that the nanospheres obtained in good monodispersion with a diameter of approximately 230 nm. The doxorubicin (DOX) loading capacity of the DOX-BSA-NPs nanoparticles was determined to be approximately 180 μg/mg and 95.79 ± 3.89%. DOX was released gradually in 6 days. In vivo tumor-growth inhibition experiments showed that after treating with I-antiAFPMcAb-DOX-BSA-NPs for 14 days, the tumor volume decreased more obvious than that of other 2 time points and the control groups. All the results indicated that the radiolabeled immune albumin nanospheres I-antiAFPMcAb-DOX-BSA-NPs could significantly inhibit the hepatoma tumor growth with the strategy of combinatorial radioimmunotherapy and chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

¹³¹I radiolabeled immune albumin nanospheres loaded with doxorubicin for in vivo combinatorial therapy

Zhang

et al. 2018

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

show abstract

“…After its synthesis, the BSA-PCL conjugate was functionalized with antiepidermal growth factor receptor (anti-EGFR) antibody and utilized for targeted RIT. The anti-EGFRlabeled particles exhibited higher cytotoxicity in vitro and in vivo, and higher cellular and tumor uptake in murine cancer models, when compared to particles without the antibody [85]. In a similar rationale, PEGylated liposomes linked to PCL-BSA, functionalized with an RGD peptide and labeled with 131 I, were tested against lung cancer in NCI-H460 tumor-bearing mice, and showed great potential as cancer theranostic agents [86].…”

Section: Radiolabeled Nanoparticles In Nuclear Oncologymentioning

confidence: 99%

Radiolabeled Nanoparticles in Nuclear Oncology

2018

View full text Add to dashboard Cite

A B S T R A C TDuring recent years, a plethora of pioneering radiolabeled nanoparticles have grown to be an integral part of nuclear medicine as theranostic tools. Herein, we focus on the most representative examples of nanoparticles of the past decade, which have been investigated in conjunction with radioisotopes aiming to serve as drug delivery or imaging agents. The present review highlights the key attributes of each nanosystem and the following classification of radiolabeled nanovehicles is based on increasing mass number (A) of radioisotopic elements.

show abstract

“…Radiotherapy is currently well accepted as one of the most effective remedies for cancer. Radionuclide particularly exhibits a great anticancer potential since it can be selectively delivered to lesion by labeling with special materials such as monoclonal antibody, bioactive peptide, etc., leading to a maximum biological effect and damage as little as possible to normal tissue 1 2 3 4 5 . Moreover, nuclide internal irradiation belongs to prolonged low dose rate exposure, but the total cumulative dose can get larger.…”

mentioning

confidence: 99%

A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/131I-antiAFPMcAb-GCV/MFH

Lin

Huang

Jiang

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Combination targeted therapy is a promising cancer therapeutic strategy. Here, using PEI-Mn0.5Zn0.5Fe2O4 nanoparticles (PEI-MZF-NPs) as magnetic media for MFH (magnetic fluid hyperthermia) and gene transfer vector for gene-therapy, a combined therapy, pHRE-Egr1-HSV-TK/131I-antiAFPMcAb-GCV/MFH, for hepatoma is developed. AntiAFPMcAb (Monoclonal antibody AFP) is exploited for targeting. The plasmids pHRE-Egr1-HSV-TK are achieved by incorporation of pEgr1-HSV-TK and pHRE-Egr1-EGFP. Restriction enzyme digestion and PCR confirm the recombinant plasmids pHRE-Egr1-HSV-TK are successfully constructed. After exposure to the magnetic field, PEI-MZF-NPs/pHRE-Egr1-EGFP fluid is warmed rapidly and then the temperature is maintained at 43 °C or so, which is quite appropriate for cancer treatment. The gene expression reaches the peak when treated with 200 μCi 131I for 24 hours, indicating that the dose of 200 μCi might be the optimal dose for irradiation and 24 h irradiation later is the best time to initiate MFH. The in vitro and in vivo experiments demonstrate that pHRE-Egr1-HSV-TK/131I-antiAFPMcAb-GCV/MFH can greatly suppress hepatic tumor cell proliferation and induce cell apoptosis and necrosis and effectively inhibit the tumor growth, much better than any monotherapy does alone. Furthermore, the combination therapy has few or no adverse effects. It might be applicable as a strategy to treat hepatic cancer.

show abstract

Radionuclide therapy using 131I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression

Cited by 28 publications

References 38 publications

¹³¹I radiolabeled immune albumin nanospheres loaded with doxorubicin for in vivo combinatorial therapy

¹³¹I radiolabeled immune albumin nanospheres loaded with doxorubicin for in vivo combinatorial therapy

Radiolabeled Nanoparticles in Nuclear Oncology

A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/131I-antiAFPMcAb-GCV/MFH

Contact Info

Product

Resources

About

Radionuclide therapy using 131I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression

Cited by 28 publications

References 38 publications

131I radiolabeled immune albumin nanospheres loaded with doxorubicin for in vivo combinatorial therapy

131I radiolabeled immune albumin nanospheres loaded with doxorubicin for in vivo combinatorial therapy

Radiolabeled Nanoparticles in Nuclear Oncology

A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/131I-antiAFPMcAb-GCV/MFH

Contact Info

Product

Resources

About

¹³¹I radiolabeled immune albumin nanospheres loaded with doxorubicin for in vivo combinatorial therapy

¹³¹I radiolabeled immune albumin nanospheres loaded with doxorubicin for in vivo combinatorial therapy